Search

Rocket Pharmaceuticals Inc

Open

SectorGezondheidszorg

2.48 2.06

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

2.38

Max

2.48

Belangrijke statistieken

By Trading Economics

Inkomsten

171M

123M

EPS

-0.15

Werknemers

202

EBITDA

179M

134M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+289.34% upside

Dividenden

By Acuity

Volgende Winsten

4 nov 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-147M

250M

Vorige openingsprijs

0.42

Vorige sluitingsprijs

2.48

Rocket Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

30 okt 2026, 19:53 UTC

Rocket Pharmaceuticals, Inc. shares fell sharply after pulling back from an early session high, remaining above its 20-day moving average.

29 okt 2026, 20:07 UTC

Rocket Pharmaceuticals, Inc. shares declined, pulling back from an earlier peak.

28 okt 2026, 22:21 UTC

Rocket Pharmaceuticals, Inc. shares are lower in after-market trading, reversing earlier gains to reach their lowest point of the day.

27 okt 2026, 20:01 UTC

Rocket Pharmaceuticals, Inc. shares are up sharply, showing strong momentum with a peak return exceeding 10% since Monday's close.

26 okt 2026, 20:07 UTC

Rocket Pharmaceuticals Inc shares are declining, having reached a session low earlier before recovering slightly, but remain below the 20-day moving average.

23 okt 2026, 20:07 UTC

Rocket Pharmaceuticals Inc shares are declining amid a broadly lower market, influenced by mixed economic indicators and rising oil prices raising inflation concerns.

22 okt 2026, 20:07 UTC

Rocket Pharmaceuticals Inc shares are trading sharply higher, rebounding from a recent decline, as the broader market experiences significant upward movement.

21 okt 2026, 22:21 UTC

Rocket Pharmaceuticals Inc. advanced sharply in after-market trading, closing at its peak.

20 okt 2026, 20:21 UTC

Rocket Pharmaceuticals Inc gained sharply in after-market trading, rising since Tuesday's close.

19 okt 2026, 20:07 UTC

Correlated Moves

Rocket Pharmaceuticals shares are higher, supported by positive clinical trial results in the biotech sector, alongside gains in the SPDR S&P Biotech ETF.

16 okt 2026, 21:01 UTC

Rocket Pharmaceuticals Inc shares advanced in after-market hours on Friday.

15 okt 2026, 20:02 UTC

Rocket Pharmaceuticals Inc is trading sharply higher, reversing a recent trend of declines after closing lower in each of the previous four sessions.

13 okt 2026, 20:01 UTC

Rocket Pharmaceuticals Inc shares fell sharply, continuing a downward trend amid broader market weakness, remaining well below their 20-day moving average.

12 okt 2026, 20:06 UTC

Rocket Pharmaceuticals Inc shares are declining, continuing a downward trend since Friday, finishing near session lows and significantly below its 20-day moving average.

9 okt 2026, 21:10 UTC

Rocket Pharmaceuticals Inc is advancing in after-market trading, showing a notable increase since Friday's close while remaining near the lower end of its one-month range.

8 okt 2026, 23:10 UTC

Rocket Pharmaceuticals Inc is trading higher in after-market hours, moving up since Thursday's close despite pulling back from an earlier peak.

7 okt 2026, 20:07 UTC

Social Media
News

Rocket Pharmaceuticals' gene therapy candidate RP-A501 shows promising initial results; shares are higher since Tuesday, despite earlier intraday weakness.

6 okt 2026, 22:01 UTC

News

Rocket Pharmaceuticals secures a $150 million credit facility with Hercules Capital to bolster its financial position and support its Phase 2 study of RP-A501.

5 okt 2026, 20:06 UTC

Rocket Pharmaceuticals Inc is advancing amid a broader market recovery, despite experiencing a significant decline over the past month and remaining near its recent lows.

2 okt 2026, 19:45 UTC

Rocket Pharmaceuticals Inc shares fell sharply, continuing a downward trend since Thursday and remaining significantly below its 20-day moving average.

1 okt 2026, 21:01 UTC

Rocket Pharmaceuticals Inc advanced in after-market trading on Thursday, recovering sharply from earlier losses amid broader market challenges.

30 sep 2026, 20:07 UTC

Rocket Pharmaceuticals Inc is gaining in today's trading session, advancing since Tuesday's close, despite a pullback from earlier session highs.

29 sep 2026, 23:01 UTC

Rocket Pharmaceuticals Inc is trading modestly higher in after-market hours following Tuesday's close, despite a significant decline over the past month.

28 sep 2026, 23:26 UTC

Rocket Pharmaceuticals Inc gained in after-market hours on Monday, recovering from earlier losses, though it remains significantly lower compared to last month's close.

25 sep 2026, 23:56 UTC

Rocket Pharmaceuticals Inc is advancing in after-market trading, gaining significantly since Friday's close after a recent decline over the past month.

24 sep 2026, 20:01 UTC

Rocket Pharmaceuticals Inc shares fell sharply, reaching their lowest point of the day and remaining well below the 20-day moving average.

23 sep 2026, 23:46 UTC

Rocket Pharmaceuticals Inc saw an increase in after-market trading, recovering from an earlier session dip and advancing higher since Wednesday's close.

22 sep 2026, 23:21 UTC

Rocket Pharmaceuticals Inc is seeing a modest increase in after-market trading, building on Tuesday's close, although it remains below its 20-day moving average.

21 sep 2026, 22:06 UTC

Advanced modestly in after-market trading despite economic growth concerns.

18 sep 2026, 22:56 UTC

Rocket Pharmaceuticals Inc is trading higher in after-market hours, maintaining an upward trend since Friday's close despite being below its 20-day moving average.

Peer Vergelijking

Prijswijziging

Rocket Pharmaceuticals Inc Prognose

Koersdoel

By TipRanks

289.34% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 9.5 USD  289.34%

Hoogste 15 USD

Laagste 4 USD

Gebaseerd op 11 Wall Street-analisten die 12-maands prijsdoelen bieden voor Rocket Pharmaceuticals Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

11 ratings

7

Buy

4

Hold

0

Sell

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Rocket Pharmaceuticals Inc

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy, an inheritable cardiac disorder; and BAG3 Dilated Cardiomyopathy. It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey.
help-icon Live chat